AAVantgarde Bio has developed an engineered adeno‑associated virus (AAV) platform that can package and deliver transgenes larger than 5 kb to photoreceptor and retinal pigment epithelium cells, overcoming the size limitation of standard AAV vectors. The system provides high retinal transduction efficiency, sustained expression, and a GMP‑compatible manufacturing process, supporting clinical programs for Stargardt disease (ABCA4) and Usher 1B syndrome (MYO7A).

Anara is an AI-powered research workspace that helps academics and students accelerate literature review and knowledge synthesis. It allows users to query academic databases, extract verifiable insights from documents, and automatically generate study aids like flashcards and quizzes.

Archerdx provides a managed WordPress hosting platform that automates site deployment, DNS configuration, and performance optimization. Its centralized dashboard lets users manage domains, SSL certificates, backups, and scaling resources while continuous security monitoring and dedicated support minimize downtime. The service is aimed at small to medium businesses, agencies, and developers seeking a hassle‑free, scalable WordPress environment.

Avenzo Therapeutics is developing targeted oncology therapies that utilize novel drug delivery systems to improve the efficacy of cancer treatments. The company focuses on addressing the limitations of current therapies by advancing a pipeline of potentially best-in-class options for patients with serious diseases.

Axial Therapeutics is developing gut-restricted small molecule therapies targeting the gut-brain axis to treat conditions such as irritability associated with autism spectrum disorder and Parkinson’s disease. Their lead candidate, AB-2004, is currently undergoing a Phase 2 clinical trial to evaluate its efficacy in addressing these neurological disorders.

Be Biopharma is developing engineered B cell therapies to treat serious diseases, focusing on conditions like hemophilia B. Their approach utilizes protein-based treatments to enhance patient outcomes and improve quality of life for those affected.

Bicycle Therapeutics creates fully synthetic, bi‑cyclic peptide molecules that combine the high affinity of biologics with drug‑like pharmacokinetics, enabling precise targeting of protein‑protein interactions that are difficult for traditional small molecules or antibodies. Their platform delivers rapid tissue penetration, renal clearance, and flexible conjugation to payloads, supporting targeted drug conjugates and immune agonists for solid‑tumor oncology and a range of non‑oncology indications. The company partners with pharma, biotech, and academic groups to develop novel therapeutics for high‑unmet‑need disease targets.

Carbonbio's website does not provide details about its product or service.

Cerene provides an FDA‑cleared, office‑based cryotherapy system that ablates the endometrial lining to treat heavy menstrual bleeding without general anesthesia. Using a single‑use probe, the procedure delivers controlled freezing in under 10 minutes, allowing gynecologists to perform the treatment in a standard exam room with minimal downtime and pain.

Colorescience offers all‑mineral sunscreens that combine zinc oxide and titanium dioxide with shade‑adjusting iron oxides, delivering broad‑spectrum SPF 30‑50 without a white cast. The formulas are enriched with peptides, antioxidants, and barrier‑supporting ingredients to provide anti‑aging and soothing benefits while remaining water‑resistant and non‑comedogenic. Customers can personalize protection and shade using the brand’s online “Customize Your SPF” tool.

Crystalys Therapeutics focuses on developing new therapeutics to address significant unmet medical needs for people living with gout. The company is actively advancing its pipeline through clinical development, including ongoing Phase 3 studies. Their work aims to provide improved treatment options for patients managing this condition.

DEM BioPharma develops first-in-class cancer therapeutics focused on novel targets for solid tumors. The company advances a pipeline of proprietary drug candidates through preclinical and clinical development stages. Their work aims to introduce new treatment modalities for difficult-to-treat malignancies.

Engrail Therapeutics develops precision-targeted therapeutics for patients with life-limiting neurological disorders by leveraging expertise in molecular mechanisms and neurocircuitry. The company aims to provide effective treatments that address the unmet medical needs of individuals suffering from these debilitating conditions.

Evommune develops novel therapeutics targeting the root causes of chronic inflammatory diseases, utilizing specific antagonists like MRGPRX2 to halt disease progression and alleviate symptoms. The company aims to improve patient outcomes by advancing a clinical-stage pipeline that addresses the debilitating effects of chronic inflammation.

Grail develops the Galleri® test, a multi-cancer early detection (MCED) blood test that analyzes DNA methylation patterns to identify signals from various cancers that lack standard screening methods. This technology enables earlier cancer detection, potentially improving treatment outcomes and reducing mortality rates.

IlluminOss provides a minimally invasive intramedullary fracture fixation system that delivers a light‑curable polymer via a percutaneous catheter, forming a patient‑specific implant that conforms to the medullary canal. The system includes fluoroscopic guidance, radiopaque markers, and a dedicated instrumentation kit to enable rapid fixation of fragility, periprosthetic, and oncologic long‑bone fractures and earlier patient mobilization.

Immunitas Therapeutics utilizes single-cell genomics to develop targeted antibody-based therapies for cancer and autoimmune diseases, focusing on the CD161-CLEC2D pathway. Their lead candidate, IMT-009, is currently in clinical trials for treating refractory tumors, addressing the need for effective treatments in patients with limited options.

Interius BioTherapeutics develops in vivo lentivector gene therapies specifically targeting B cell lymphomas, utilizing programmable vectors for precise genetic medicine delivery. The company aims to provide effective treatment options for patients with challenging hematological malignancies, addressing the need for targeted therapies in oncology.

KalVista Pharmaceuticals develops oral small‑molecule protease inhibitors that target the kallikrein‑kinin pathway for hereditary angioedema (HAE). Its FDA‑approved drug EKTERLY (sebetralstat) provides rapid, on‑demand relief without injections, and the company’s pipeline includes an oral Factor XIIa inhibitor for prophylactic use. The products aim to improve convenience and speed of treatment for HAE patients and their prescribers.

Lassen Therapeutics develops fully human monoclonal antibodies targeting the interleukin-11 receptor to treat fibrotic diseases such as thyroid eye disease and idiopathic pulmonary fibrosis. Their approach aims to inhibit IL-11 signaling, addressing the underlying mechanisms of fibrosis to improve patient outcomes.

The company develops targeted immuno‑oncology biologics—including ligand‑directed antibody‑drug conjugates, engineered cytokine‑fusion proteins, and bispecific T‑cell engagers—that bind tumor‑associated antigens and reprogram the tumor microenvironment to enhance anti‑tumor immunity. It couples these therapeutics with a cloud‑based biomarker analytics suite that integrates multiplex IHC, single‑cell RNA‑seq, and circulating tumor DNA data to guide patient selection and dose optimization. The platform is offered to pharmaceutical, biotech, and academic partners developing oncology pipelines.

The startup develops small molecule therapeutics that enhance mitochondrial function to treat genetic, metabolic, and neurodegenerative disorders, as well as age-related conditions. By improving mitochondrial efficiency, these therapeutics facilitate quicker treatment initiation and increase the probability of positive patient outcomes.

Newleos Therapeutics is a clinical‑stage biotech developing oral small‑molecule drugs that target novel neuropsychiatric pathways, aiming to treat generalized anxiety, social anxiety, alcohol use disorder, and cognitive impairment with fewer side effects. Its pipeline includes a GABAA‑γ1 positive allosteric modulator and a vasopressin‑1a receptor antagonist, both designed for improved efficacy and safety compared to existing therapies.

Photys Therapeutics utilizes a proprietary platform of bifunctional small molecules to precisely control protein post-translational modifications, enhancing the phosphorylation of target proteins. This technology aims to restore protein function and amplify disease-fighting mechanisms, addressing the challenges of dysfunctional protein signaling in various diseases.